Protagonist Therapeutics IPO Advisory
Share this IPO Profile:
Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Protagonist Therapeutics, and our comprehensive analysis, click "
Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Protagonist Therapeutics | PTGX - NASDAQ |
$12.00-$12.00 |
$12.00 |
$12.00 | 7.5 million | 8/11/2016 |
Leerink Partners, Barclays, BMO Capital Markets |
Co-Manager(s): |
Health Care |
Filing(s): Filed 2016-07-11 Terms Added 2016-08-01
|
Protagonist Therapeutics Quote & Chart - Click for current quote -
PTGX
About Protagonist Therapeutics (adapted from Protagonist Therapeutics prospectus):
They are a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address significant unmet medical needs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PTGX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2025 IPO Boutique. All Rights Reserved